FGH BioTech Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.08M

  • Investors
  • 2

FGH BioTech General Information

Description

Developer of small-molecule drugs designed to treat metabolic disorders and cancer. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins, enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes, and lipid disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 414 Thamer Circle
  • Houston, TX 77024
  • United States
+1 (713)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 414 Thamer Circle
  • Houston, TX 77024
  • United States
+1 (713)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

FGH BioTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 19-May-2018 $2.08M Completed Generating Revenue
3. Later Stage VC (Series A) 18-Mar-2016 Completed Generating Revenue
2. Angel (individual) 06-Nov-2015 Cancelled Generating Revenue
1. Grant 01-Jan-2014 $1.84M Completed Generating Revenue
To view FGH BioTech’s complete valuation and funding history, request access »

FGH BioTech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view FGH BioTech’s complete cap table history, request access »

FGH BioTech Patents

FGH BioTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020132700-A1 Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof Inactive 21-Dec-2018
AU-2017323521-A1 Di-substituted pyrazole compounds for the treatment of diseases Active 07-Sep-2016
AU-2017323521-B2 Di-substituted pyrazole compounds for the treatment of diseases Active 07-Sep-2016
AU-2017323521-B9 Di-substituted pyrazole compounds for the treatment of diseases Active 07-Sep-2016
CA-3036195-A1 Di-substituted pyrazole compounds for the treatment of diseases Active 07-Sep-2016 C07D401/14
To view FGH BioTech’s complete patent history, request access »

FGH BioTech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
BCM Ventures Venture Capital Minority
U.S. Department of Health and Human Services Government
To view FGH BioTech’s complete investors history, request access »

FGH BioTech FAQs

  • When was FGH BioTech founded?

    FGH BioTech was founded in 2011.

  • Where is FGH BioTech headquartered?

    FGH BioTech is headquartered in Houston, TX.

  • What industry is FGH BioTech in?

    FGH BioTech’s primary industry is Drug Discovery.

  • Is FGH BioTech a private or public company?

    FGH BioTech is a Private company.

  • What is FGH BioTech’s current revenue?

    The current revenue for FGH BioTech is .

  • How much funding has FGH BioTech raised over time?

    FGH BioTech has raised $7.08M.

  • Who are FGH BioTech’s investors?

    BCM Ventures and U.S. Department of Health and Human Services have invested in FGH BioTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process